



June 12, 2003

FILE COPY

Mr. Arthur Y. Tsien
Olsson, Frank & Weeda, P.C.
1400 16th Street, N.W.
Suite 400
Washington, DC 20036-2220

Dear Mr. Tsien:

Your petition requesting the Food and Drug Administration to determine that Lovenox (enoxaparin sodium), NDA 20-164 (90mg/0.6ml) (Product Number 006), sponsored by Aventis Pharmaceuticals inc., was not withdrawn from sale for reasons of safety or effectiveness was received by this office on 06/02/2003. It was assigned docket number 2003P-0266/CP 1 and it was filed on 06/02/2003. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note the acceptance of the petition for filing is a procedural matter in that no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe
Dockets Management Branch

2003P-0266

ACK 1